Venn Life Sciences Holdings PLC AGM Statement (5858R)

TIDMVENN

RNS Number : 5858R

Venn Life Sciences Holdings PLC

30 June 2015

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")

AGM Statement

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology, academic and medical device clients, will hold its Annual General Meeting today at Finsgate, 5-7 Cranwood Street, London EC1 V9EE at 11am.

Following the formal proceedings of the meeting the Chief Executive Officer, Tony Richardson, will provide the following statement:

I am delighted to report that the success that we achieved last year has continued into 2015 with further solid trading in the first half of the year. Our increasing capacity to win larger contracts was reinforced by the EUR4.1m contract wins announced in March from a US based Biotechnology company, as well as the more recent contract with a leading European Biotechnology company worth EUR2m. Our new business success rate to date has been encouraging and we have a good pipeline of potential contracts that we are working hard to convert. Following the March Placing, which raised GBP2m, the business is well funded to make the investment needed in business development, support systems and in key clinical operations staff to service the larger contract tenders that we are now approaching.

Progress with Labskin continues following our first sales and we are confident of seeing commercial success this year with these products. We also continue to look at a number of acquisition opportunities and look forward to providing further information as these progress.

I am delighted to welcome Jonathan Hartshorn, who started with us earlier this month as Chief Financial Officer, and I look forward to introducing him to shareholders a little later.

Finally, I would like to thank shareholders for their continued support and we look forward to a successful 2015, and beyond, for Venn.

Enquiries:

 
Venn Life Sciences Holdings Plc                                  www.vennlifesciences.com 
Tony Richardson, Chief Executive Officer                             Tel: +353 154 99 341 
Orla Mc Guinness, Marketing Manager                                  Tel: +353 153 73 269 
 
Zeus Capital (Nominated Adviser and                                    Tel: 0161 831 1512 
 Broker) 
 Ross Andrews/Andrew Jones 
Alex Davies                                                            Tel: 020 7533 7727 
 
Walbrook PR Ltd                           Tel: +44 (0)20 7933 8780 or venn@walbrookpr.com 
Paul McManus                                                     Mob: +44 (0)7980 541 893 
Lianne Cawthorne                                                 Mob: +44 (0)7584 391 303

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGMUKAURVUANUUR

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024